About Contact Us Careers

Migraine Treatment Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2752
Published Date: Oct 18, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Migraine Drugs Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Eli Lilly and Company
Eisai Co. Ltd.
Amneal Pharmaceuticals Inc.
Abbott Laboratories
Novarties International AG
Amgen Inc.
Teva Pharmaceuticals Industries
Endo International Plc.

Browse Key Market Insights with Data Illustration:

Migraine Drugs Market Size & Share, Growth Trends 2036

In the News

On February 15, 2020, a new prescription medication Reyvow was approved by the Drug Enforcement Application (DEA) to provide treatment for acute migraines and associated symptoms such as nausea and sensitivity to light & sound. This medicine is especially for patients having disabling problems and who do not respond to medicines.

Author Credits: Radhika Pawar

Report ID: 2752
Published Date: Oct 18, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of migraine drugs is assessed at USD 6.09 billion.

Migraine Drugs Market size was over USD 5.57 billion in 2023 and is projected to reach USD 23.2 billion by 2036, growing at around 11.6% CAGR during the forecast period i.e., between 2024-2036.

North America industry is estimated to hold largest revenue share by 2036, due to increasing adoption of novel therapies and high prevalence of migraine.

The major players in the market are Pfizer Inc., Eli Lilly and Company, Eisai Co. Ltd., Amneal Pharmaceuticals Inc., Abbott Laboratories, Novarties International AG, Amgen Inc., Teva Pharmaceuticals Industries, Endo International Plc., and others.

Inquiry Before Buying Request Free Sample